The introduction of targeted therapy has revolutionized the treatment of chronic myeloid
leukemia (CML). The pivotal role of the Philadelphia chromosome, resulting from the …

Imatinib mesylate is currently the standard therapy for chronic myeloid leukemia (CML)
patients. Despite the remarkable results achieved with imatinib, the emergence of resistance …

Introduction: Chronic myelogenous leukemia (CML) is a progressive and often fatal
hematopoietic neoplasm. The Bcr-Abl tyrosine kinase inhibitor imatinib mesylate …

The therapeutic landscape of chronic myeloid leukemia (CML) has changed dramatically in
the last decade. In particular, the availability of imatinib mesylate, a tyrosine kinase inhibitor …

Chronic myelogenous leukemia (CML) is a myeloproliferative disorder arising from a single
genetic mutation that leads to an increase in immature myeloid cells in the bone marrow and …

The development of imatinib has resulted in sustained hematologic and cytogenetic
remissions in all phases of chronic myeloid leukemia (CML). Despite the high efficacy …

Nilotinib, a second-generation tyrosine kinase inhibitor, was designed to overcome
resistance of a wide range of BCR-ABL mutants to imatinib. When used in the first-line …

Chronic myeloid leukemia (CML) is a clonal disease of the hematopoietic stem cells that is
characterized by excessive proliferation, but retains of the capacity for differentiation …

The successful introduction of the tyrosine kinase inhibitors has initiated a new era in the
management of chronic myeloid leukemia (CML). Imatinib mesilate therapy has significantly …

Abstract Tyrosine Kinase Inhibitors brought a revolution in the management of chronic
myeloid leukemia. Long term disease free survival became a reality for the majority of …